HaimaThr's profile picture. We are a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for treatment of bleeding and other blood-related ailments.

Haima Therapeutics

@HaimaThr

We are a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for treatment of bleeding and other blood-related ailments.

Haima is seeking a postdoc to support our CMC activities. Please see the job description and contact us ASAP. haimatherapeutics.com/2023postdoc @JishnuSenGupta @macky_neal @tjpelura @PhilSpinellaMD @JerroldLevy


Haima is looking for a motivated young scientist to join our team as an industry postdoc with potential to transition to a full time role with the company. Message me directly at [email protected] or through Linkedin linkedin.com/jobs/view/3682…


We are proud to announce the official announcement of @macky_neal as our #CMO and @sflaim to our Board! haimatherapeutics.com/2023nealflaim


Haima Therapeutics reposted

Exciting to see our successful collaboration lead to such an impactful paper in a great journal like @BloodJournal Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in Von Willebrand disease murine models ashpublications.org/blood/article-…


Our Nanotechnology-Enabled Biosynthetic Whole-Blood Surrogate for Hemostatic Resuscitation project was recently highlighted by DoD cdmrp.health.mil/crrp/research_…


Haima Therapeutics reposted

Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI

DARPA's tweet image. Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI

Haima Therapeutics reposted

I hope this announcement is the future of #transfusionmedicine and #trauma resuscitation. Motivated and excited for @PittTTMRC to help lead this collaboration with @JishnuSenGupta @KaloCyte @UofMaryland @HaimaThr @PhilSpinellaMD @SMSheaLab and so many more @UPMCnews @PittTweet

Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI

DARPA's tweet image. Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI


Haima Therapeutics reposted

I am happy to share this exciting new @DARPA project to develop and test Field Deployable Whole Blood Equivalent. Such an honor and privilege to be a part of this dream team of blood enthusiasts! @JishnuSenGupta @UofMaryland @KaloCyte @HaimaThr @CaseEngineer @cwru @OhioState


Haima Therapeutics reposted

Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI

DARPA's tweet image. Bleeding is the most common cause of potentially survivable death in trauma, in both military and civilian settings. DARPA has selected a team to begin work on a Field-deployable whole blood equivalent. ow.ly/jVJE50MFBAI


Can’t wait to be at BIO 2022 in San Diego, June 13-16! Join me at BIO’s stellar networking events to seize today’s unprecedented momentum and make a LIMITLESS future a reality at the world’s largest event for the biotech industry. #BIO2022


Very nice write-up on a new, but integral part of Haima's team. @AndrewDitto comes with great experience, leadership, and insight to our young company as we grow. @uakron produces great graduates! @JishnuSenGupta uakron.edu/engineering/gr…


Haima Therapeutics receives $3M from the U.S. Department of Defense to study its Synthetic Platelet Technology in combination with Other Blood Surrogate Products haimatherapeutics.com/news/dodgrants…


Congratulations to our Chief Scientific Advisor, @JishnuSenGupta on being elected as a 2021 @aimbe Fellow. His contributions to science and engineering have led to our previous, ongoing, and future success. aimbe.org/press/sengupta…


So proud to have these #WomeninSTEM moving our therapeutic program forward. #ChristaPawlowski, @sanasyed15 #JenPaiz, and #EmilyGahagan. Also our interns #aashkashah, #asyaorhan, and #graceschlemmer. Finally, our SAB member, @BethShaz. Thank you!

HaimaThr's tweet image. So proud to have these #WomeninSTEM moving our therapeutic program forward. #ChristaPawlowski, @sanasyed15 #JenPaiz, and #EmilyGahagan. Also our interns #aashkashah, #asyaorhan, and #graceschlemmer. Finally, our SAB member, @BethShaz. Thank you!

Haima Therapeutics Announces the Appointment of Dr. Beth Shaz to its Scientific Advisory Board haimatherapeutics.com/news/shaz


Haima Therapeutics Announces the Appointment of Dr. Wolfgang Bergmeier to its Scientific Advisory Board haimatherapeutics.com/news/bergmeier


United States Trends

Loading...

Something went wrong.


Something went wrong.